

1 **Transcutaneous vagus nerve stimulation in humans induces pupil**
2 **dilation and attenuates alpha oscillations**

3 Omer Sharon¹, Firas Fahoum^{2,3}, Yuval Nir^{1,4,5}

4 1. Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University,
5 Israel, Tel Aviv 69978, Israel; 2. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978,
6 Israel; 3. EEG and Epilepsy Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Tel,
7 Aviv, Israel; 4. Sagol School of Neuroscience, Sagol School of Neuroscience, Tel Aviv 69978, Israel;
8 5. Functional Neurophysiology and Sleep Research Lab, Tel-Aviv Sourasky Medical Center, Tel Aviv,
9 Israel

10 Corresponding author email address: yuvalnir.tau@gmail.com

11 Conflict of interest: none

12

1 **Abstract**

2 Vagus nerve stimulation (VNS) is widely used to treat drug-resistant epilepsy and depression.
3 While the precise mechanisms mediating its long-term therapeutic effects are not fully resolved,
4 they likely involve locus coeruleus (LC) stimulation via the nucleus of the solitary tract (NTS),
5 which receives afferent vagal inputs. In rats, VNS elevates LC firing and forebrain
6 noradrenaline levels, whereas LC lesions suppress VNS therapeutic efficacy. Non-invasive
7 transcutaneous VNS (tVNS) employs electrical stimulation that targets the auricular branch of
8 the vagus nerve at the cymba conchae of the ear. However, the extent that tVNS mimics VNS
9 remains unclear. Here, we investigated the short-term effects of tVNS in healthy human male
10 volunteers (n=24), using high-density EEG and pupillometry during visual fixation at rest. We
11 compared short (3.4s) trials of tVNS to sham electrical stimulation at the earlobe (far from the
12 vagus nerve branch) to control for somatosensory stimulation. Although tVNS and sham
13 stimulation did not differ in subjective intensity ratings, tVNS led to robust pupil dilation
14 (peaking 4-5s after trial onset) that was significantly higher than following sham stimulation.
15 We further quantified, using parallel factor analysis, how tVNS modulates idle occipital alpha
16 (8-13Hz) activity identified in each participant. We found greater attenuation of alpha
17 oscillations by tVNS than by sham stimulation. This demonstrates that tVNS reliably induces
18 pupillary and EEG markers of arousal beyond the effects of somatosensory stimulation, thus
19 supporting the hypothesis that tVNS elevates noradrenaline and other arousal-promoting
20 neuromodulatory signaling, and mimics invasive VNS.

21

1 **Significance statement**

2 Current non-invasive brain stimulation techniques are mostly confined to modulating cortical
3 activity, as is typical with transcranial magnetic or transcranial direct/alternating-current
4 electrical stimulation. Transcutaneous vagus nerve stimulation (tVNS) has been proposed to
5 stimulate subcortical arousal-promoting nuclei, though previous studies yielded inconsistent
6 results. Here we show that short (3.4s) tVNS pulses in naïve healthy male volunteers induced
7 transient pupil dilation and attenuation of occipital alpha oscillations. These markers of brain
8 arousal are in line with the established effects of invasive VNS on locus coeruleus-
9 noradrenaline signaling, and support the notion that tVNS mimics VNS. Therefore, tVNS can
10 be used as a tool for studying the means by which endogenous subcortical neuromodulatory
11 signaling affects human cognition, including perception, attention, memory, and decision-
12 making; and also for developing novel clinical applications.

1 **Introduction**

2 Since 1988, vagus nerve stimulation (VNS) has been successfully used to reduce epileptic
3 seizures in patients with drug-resistant epilepsy (Krahl and Clark, 2012), and has demonstrated
4 clinical effectiveness for many patients treated with invasive VNS (Boon et al., 2018; Kwon et
5 al., 2018). VNS is also applied as a treatment for drug resistant major depression (e.g Nemeroff
6 et al., 2006).

7 VNS modulates vagal afferent inputs to the brainstem Nucleus Tractus Solitarius, which
8 subsequently activate the locus coeruleus-noradrenaline (LC-NE) system. Indeed, in rats, VNS
9 increases LC neuronal discharges (Takigawa and Mogenson, 1977; Groves et al., 2005; Hulsey
10 et al., 2017) and elevates NE levels in the hippocampus and cortex (Dorr and Debonnel, 2006;
11 Roosevelt et al., 2006). The effects of VNS on LC-NE are considered key to reducing seizures.
12 This is due to the strong positive correlation observed of the noradrenergic and anticonvulsive
13 effects of VNS (Raedt et al., 2011), and due to the elimination of the anticonvulsive effects by
14 means of the chemical lesions of the LC (Krahl et al., 1998). VNS also modulates signaling in
15 other neuromodulatory pathways such as the serotonergic, dopaminergic, and cholinergic
16 systems (Dorr and Debonnel, 2006; Manta et al., 2009; Mridha et al., 2019). However, some of
17 these effects are likely to be secondary, i.e. occur later and with mediation through the LC-NE
18 system (Dorr and Debonnel, 2006).

19 In humans, invasive VNS induces markers of brain arousal that are consistent with LC-NE
20 activity. This includes pupil dilation (Desbeaumes Jodoin et al., 2015), which is tightly linked
21 with LC-NE activity (Joshi et al., 2016; Reimer et al., 2016; Gelbard-Sagiv et al., 2018; Hayat
22 et al., 2020). VNS may also lead to EEG desynchronization, but the effects are subtler than in
23 pupil dilation, at least regarding the clinical parameters that typically employ long (30-60s)
24 stimulation epochs. Accordingly, early studies with <10 patients each, did not find VNS effects
25 on spontaneous intracranial EEG (Hammond et al., 1992) or scalp EEG (Salinsky and Burchiel,
26 1993). In contrast, a more recent study with 19 participants, which analyzed separately VNS

1 ‘responders’ and ‘non-responders’, observed EEG desynchronization in the alpha and delta
2 bands (Bodin et al., 2015).

3 Non-invasive transcutaneous vagal nerve stimulation (tVNS) applies electrical current at a high
4 frequency (typically 25Hz) through the left ear, targeting the auricular branch of the vagus nerve
5 at the cymba conchae (Figure 1) (for anatomic evidence see Van Bockstaele et al., 1999;
6 Bermejo et al., 2017). tVNS has been shown to mimic the anticonvulsive and antidepressant
7 effects of invasive VNS (Stefan et al., 2012; He et al., 2013; Hein et al., 2013; Bauer et al.,
8 2016; Rong et al., 2016; Trevizol et al., 2016), and has demonstrated safety and tolerability
9 (Redgrave et al., 2018). Beyond the clinical efficacy of tVNS, interest has grown regarding its
10 use in healthy individuals for basic neuroscience research (Van Leusden et al., 2015). However,
11 the literature is inconsistent as to the extent that tVNS mimics the effects of invasive VNS on
12 EEG or pupil dilation; such evidence would suggest LC-NE involvement (Ventura-Bort et al.,
13 2018; Warren et al., 2018; Keute et al., 2019). We suspect that the discrepancies stem from
14 employing long (e.g. 30sec) stimulation epochs as in clinical applications, and due to the
15 indirect focus on the P300 component in which LC-NE activity is assumed to play a key role.

16 Here, we set out to examine if short-term tVNS induces EEG and pupillary markers of arousal,
17 as is in the context of VNS-induced activation. We used short (3.4s) stimulation pulses during
18 task-free rest conditions in healthy naïve male volunteers (to avoid long-term changes
19 associated with therapeutic effects (Follesa et al., 2007; Manta et al., 2013)). We hypothesized
20 that if indeed tVNS increases LC and neuromodulatory activities, it should lead to pupil
21 dilation, as has been observed across multiple species (Joshi et al., 2016; Reimer et al., 2016;
22 Hayat et al., 2020). In addition, we hypothesized that tVNS would attenuate alpha oscillations
23 that are anti-correlated with arousal during rest (Torsvall and Akerstedt, 1987a; Drapeau and
24 Carrier, 2004a; Amzica and Lopes da Silva, 2017), and that are attenuated by invasive VNS
25 (Bodin et al., 2015). In line with these predictions, we found that tVNS induces pupil dilation
26 and alpha desynchronization above and beyond the effects of sham (somatosensory)
27 stimulation.

1 **Materials and methods**

2 **Participants**

3 High-density (256-channel) EEG and pupillometry were recorded in 25 healthy young male
4 adults (mean age: 28.08 ± 5.84 years, 2 left-handed). Written informed consent was obtained
5 from each participant. The study was approved by the Medical Institutional Review Board
6 (IRB) at the Tel Aviv Sourasky Medical Center. Females of child bearing age were not
7 included, per guidelines of the approved IRB. Participants reported being healthy and without
8 a history of neuropsychiatric disorders; they indicated their dominant eye for pupillometry. One
9 participant was excluded from the analysis due to excessive blinking, after which 24
10 participants remained (mean age: 28.3 ± 1.2). Data from an additional three participants were
11 excluded from the EEG analysis due to lack of alpha activity, after which 21 participants
12 remained for the EEG analysis (mean age 28.01 ± 1.3).

13 **Experimental design**

14 **Main experiment.** After the EEG setup (see below), participants performed a short ‘method of
15 limits’ procedure to select tVNS/sham stimulation intensities while sitting. This procedure
16 systematically identifies the maximal comfortable stimulation levels for each individual, as in
17 (Kraus et al., 2013; Yakunina et al., 2017; Ventura-Bort et al., 2018). We applied 5s-long
18 stimulation trials, starting at 0.1mA, and increasing in each trial by 0.2mA. After each trial,
19 participants rated the subjective intensity on a scale of 0-9 ([0] = no sensation; [3] = light
20 tingling; [6] = strong tingling; [9] = painful). We continued increasing the current until either
21 reaching a level rated as [9] or a maximal level of 5mA. This procedure was carried out twice
22 for each stimulation location (real tVNS at the cymba conchae vs. sham stimulation at the ear
23 lobe). The mean currents corresponding to a subjective rating of [8] (just below painful) were
24 selected, for each stimulation location separately. Thus, tVNS intensity was adjusted for each
25 participant and location separately, as above the detection threshold and below the pain
26 threshold, as is done in clinical settings (Ellrich, 2011). Participants were then instructed to

1 position their heads in a chin-rest apparatus for adjusting and calibrating the eye-tracker (see
2 below). Subsequently, participants were instructed to fixate on a white cross on a background
3 of a gray computer screen (HP model 2311x, positioned 80cm from the participants' eyes),
4 throughout experimental "blocks" lasting 5 minutes. Each block included 11 trials of 3.4s
5 stimulation epochs (in each trial, tVNS intensity was ramped up gradually, to the level defined
6 above), separated by inter-stimulus-intervals of 26s (± 1 s jitter). We performed two blocks of
7 either tVNS or sham, and then switched to position the stimulating electrode in the alternate
8 location (the order was counterbalanced), to reach a total of eight blocks per session (Figure
9 1C). Before changing the electrode location, participants answered questions regarding their
10 subjective experience of stimulation (Table 1). Participants were free to rest between the blocks
11 ad lib. Data acquired during these "breaks" were used to characterize alpha activity in each
12 individual during non-experimental conditions (see below).

13 **Pilot experiment.** A similar experiment using the same device with a separate group of 29 male
14 participants (mean age: 26.82 ± 1.1 years, 4 left-handed) used the default clinical stimulation
15 mode (30s on, 30s off) during fixation at rest, while recording high-density EEG (n=15) and
16 pupillometry (n=29).


17 **Transcutaneous vagus nerve stimulation (tVNS)**

18 tVNS was delivered using NEMOS®, (Cerbomed, Germany, now tVNS technologies; Figure
19 1B). In the tVNS condition, the electrodes were placed at the left cymba conchae, which is
20 heavily innervated by the auricular branch of the vagus nerve (Peuker and Filler, 2002; Safi et
21 al., 2016; Badran et al., 2018) (Figure 1A). In the sham condition, the electrodes were placed
22 at the left earlobe (Figure 1A), which is not expected to induce brainstem or cortical activation
23 (Kraus et al., 2007; Sellaro et al., 2015; Steenbergen et al., 2015). Pulses (200-300 μ s width)
24 were delivered at a rate of 25Hz (duty cycle of ~7% ON time) for 3.4s. This included ramping
25 up of intensity (as set by the device) to a level experienced as just-below painful, adjusted for
26 each participant and condition separately ('method of limits' procedure above), as is often set

1 clinically in patients (Vonck et al., 2014). To achieve 3.4s stimulation trials, we controlled the
2 NEMOS stimulation device using linear actuators (Actounix, Canada) that pressed the ON/OFF
3 button automatically according to programmable times. These actuators were controlled by
4 Arduino mega (Arduino, Italy), directed by Psychopy python package (Peirce, 2007). Two
5 additional measures verified good electrode contact throughout, and consistent effectiveness of
6 the stimulation: (i) the NEMOS device stops stimulation automatically whenever good physical
7 contact with the participant's skin is disrupted, and (ii) the experimenter verified in each
8 participant the presence of a visually-evident 25Hz stimulation artifact in EEG electrodes close
9 to the left ear.

10

11 **Figure 1: Experimental design**



12

13 **Legend:** (A) Schematic illustration of the rationale of tVNS (B) Stimulation electrode
14 placement – (1) location of the tVNS on the cymba conchae of the left ear (2) location of the
15 sham stimulation on the left earlobe (3) photo of the commercial stimulation electrode. (C)
16 Experimental design, each experiment started with a ‘method of limits’ procedure in order to
17 adjust the stimulation current according to the individual subjective pain report (Rating); and
18 then increased incrementally by 0.2 mA until a current matched to a rating of 8 was selected.
19 Eight blocks were then conducted, each of 5min and including 11 stimulation trials of 3.4s and
20 stimulation intervals of 25-27s.

1 **Pupillometry**

2 **Data acquisition.** Eye movements/gaze and pupil size were recorded monocularly from the
3 dominant eye using an infrared video-oculographic system with a chin-rest (Eyelink 1000 Plus,
4 SR Research). Gaze and pupil data were sampled at 500Hz, and positions were converted to
5 degrees of visual angle based on a 9-point calibration performed at the beginning of the
6 experiment (on mid-gray background). The experiment was carried out in a room with constant
7 ambient light.

8 **Data analysis.**

9 Pupil data were low-pass filtered, using a 10Hz 4th-order Butterworth filter with a zero-phase
10 shift. Periods of blinks were detected using the manufacturer's standard algorithms, with default
11 settings. The remaining data analyses were performed using custom-made Matlab scripts (The
12 MathWorks). Blinks were removed by linear interpolation of values measured 100ms before
13 and after each identified blink (de Gee et al., 2014). Peri-trial data were segmented by extracting
14 pupil data [-10s +13.4s] around each stimulation trial. Trials in which interpolated data
15 accounted for > 50% of the data points were excluded (van Steenbergen and Band, 2013). After
16 excluding one participant who had no trials remaining, the process yielded a mean of
17 42.12 ± 1.79 trials in the tVNS condition and 42.16 ± 1.79 in the sham condition (of 45, range 42-
18 45 for both). To enable averaging across participants with different pupil sizes while avoiding
19 arbitrary units, we converted pupil data to 'percent change' values relative to a 10s baseline
20 prior to stimulation: $[(x - \text{baseline}) / \text{baseline}] * 100$, as in (Reimer et al., 2016; Liu et al., 2017).
21 Baseline pupil values did not differ significantly between the tVNS and sham conditions. In
22 both conditions, the smaller the pupil before a specific trial, the higher the chance of observing
23 significant pupil dilation ($R = -0.27$, $p < 10^{-20}$, see Discussion).

24 The resulting pupil time-courses were the mean values across trials for each participant and
25 condition separately, as depicted in Figure 2A (for visualization only, single participant traces
26 were band-pass filtered again between 0.01-10Hz, as shown in Figure 2C). To present the

1 individual participant data, we reduced the pupil data for each participant and condition to a
2 scalar value (Figure 2B), by averaging the time-course across trials in the interval between the
3 two points of half maximum (FDHM, 3.2-10.4s) following stimulation onset (see the dashed
4 bar in Figure 2A).

5 Gaze data and blink rate were also inspected and compared between conditions. Gaze was
6 extracted, interpolated, and averaged using the same procedure described above for pupil size.
7 Data points marked as blinks were summed across participants to produce a blink rate that was
8 time-locked to stimulation onset.

9 **EEG**

10 **Data acquisition.** High-density EEG was recorded continuously using a 256-channel hydrocel
11 geodesic sensor net (Electrical Geodesics, Inc. [EGI], Eugene OR, USA). Each carbon-fiber
12 electrode, consisting of a silver chloride carbon fiber pellet, a lead wire, and a gold-plated pin,
13 was injected with conductive gel (Electro-Cap International). Signals were referenced to Cz,
14 amplified via an AC-coupled high-input impedance amplifier with an antialiasing analog filter
15 (NetAmps 300, EGI), and digitized at 1000 Hz. Electrode impedance in all sensors was verified
16 to be $<50\text{ k}\Omega$ before starting the recording.

17 **EEG data analysis.** EEG preprocessing was performed in Matlab using custom-written code
18 and the FieldTrip toolbox (Oostenveld et al., 2011). First, we used a subsample of 192
19 electrodes placed directly on the skull (avoiding cheek electrodes with higher muscle artifacts).
20 Continuous data from these electrodes were segmented to 33s epochs, [-15s +18s] around each
21 stimulation onset. To enable effective visual inspection, data epochs were initially de-trended
22 linearly, notch-filtered (at 50Hz), and high-pass ($>0.1\text{ Hz}$) filtered using a 2nd order Butterworth
23 filter to remove DC shifts. We then visually confirmed that all sham and tVNS trials showed
24 25Hz stimulation artifact around the left ear. Trials without the artifact were excluded (a mean
25 of $14.75\% \pm 3.08$ trials were excluded). To focus on alpha oscillations, data were further band-
26 passed filtered at two frequencies. The first filter was applied at 5-15Hz using a 3rd-order two-

1 pass Butterworth filter, as in previous parallel factor analysis (PARAFAC) studies (Barzegaran
2 et al., 2017). An additional notch filter at 25Hz (stimulation frequency) was used, with
3 harmonics up to 475Hz, to remove any residual artifact stemming from stimulation and not
4 removed by previous filters. Then, we removed the minimal number of channels or trials whose
5 data crossed an absolute amplitude threshold of $100\mu\text{V}$ in an automatic iterative process – that
6 is, each 3s epoch in each channel had a Boolean value $[\max(\text{abs}(x)) > 100]$. Subsequently, in
7 each iteration, either a channel or a trial was excluded, such that a minimal number of
8 channel×trial 3s data epochs was discarded (the code is available at:
9 https://github.com/sharomer/eeg_2d_minimal_rejection). This process removed large
10 movement artifacts, but not all blink artifacts, which were separated later using the parallel
11 factor analysis.

12 This preprocessing resulted in identifying a mean number of $18.76 \pm 2.86\%$ unacceptable
13 channels per participant (of 192, data were interpolated using a linear distance weighted
14 interpolation), and a mean number of $22 \pm 3.42\%$ unacceptable trials per participant (discarded
15 from subsequent analyses). Only then, were trials classified to the tVNS or sham condition, to
16 avoid any bias in preprocessing. The mean number of valid trials in the tVNS condition was
17 35.61 ± 1.09 , and in the sham condition, 35.61 ± 1.09 (of 44, the number of trials did not differ
18 significantly between the conditions). Next, data of each trial were transformed to the time-
19 frequency domain using the Fast Fourier Transform (FFT), after multiplying by a moving
20 hamming window of 3s. This yielded a frequency resolution of 0.33Hz and a temporal
21 resolution of 0.33s.

22 **Parallel factor analysis.** We first extracted data from “break” periods (between stimulation
23 blocks) to identify each participant’s alpha topography and frequency in an unbiased manner
24 with respect to the study objectives. These data were segmented to 5s epochs, with 1s overlap
25 with the preceding epochs and 1s overlap with the subsequent epochs. The epochs were band-
26 passed filtered (as described for stimulation data, above) and reduced to 3s trials (discarding
27 the overlap) to avoid filtering artifacts at the edges. Then, “break” data epochs were cleaned as

1 described for stimulation data, using the same procedure described above (resulting in
2 117.84 ± 7.15 trials, on average, per participant, with 175.28 ± 2.71 clean channels on average).
3 These 3s time-frequency epochs were used to identify each participant's alpha topography and
4 precise frequency range using the PARAFAC analysis (Harshman, 1970), as implemented in
5 the N-way toolbox (Andersson and Bro, 2000), and as presented in Figure 3. The type of
6 constraint for each dimension was set to non-negativity. The proper number of components was
7 determined by using the Core Consistency Diagnostic (CCD), in which the number of
8 components is the highest when the minimal value of CCD is 55% and $90.60 \pm 3.18\%$ on average
9 (Bro and Kiers, 2003).

10 Next, to assess the changes in alpha oscillations during stimulation, the individual weights for
11 alpha component topography and frequency (Figure 4A) were derived from the break data, and
12 multiplied by the spectrum of all channels, such that a single channel representing the weighted
13 activity was achieved. We then subtracted the mean baseline activity in [-1:0]s relative to
14 stimulation onset, for each participant and for each trial, and calculated the mean activity across
15 participants (N=21); this yielded the results depicted in Figure 4D.

16 To assess more carefully the brain activity following stimulation, beyond the a-priori electrode-
17 and frequency-band of interest, we conducted the following analyses. (i) We rigidly set the
18 alpha topography (to investigate time-frequency changes in the entire spectrogram). To this
19 end, we used the topography of interest derived from the PARAFAC decomposition of the
20 break data (Figure 4A, lower panel), ignored the frequency of interest, plotted the entire
21 spectrogram at 5-15Hz in % change relative to the same baseline ([-1:0]s prior to stimulation
22 onset, Figure 4G,4H,4E), and used a cluster permutation test (see below). We also confirmed
23 differences between tVNS and sham conditions by means of a post-hoc direct comparison using
24 Wilcoxon signed rank tests (Results). (ii) Alternatively, we rigidly set the frequency-band of
25 interest (to investigate changes in all electrodes). To this end, we used the frequency-of-interest
26 derived from the PARAFAC decomposition of the break data (Figure 4A) and ignored the
27 topography of interest. We plotted the entire topographical changes in voltage around times of

1 stimulation, while subtracting the activity [-1:0s] prior to stimulation (Figure 4F). We then
2 performed a topographical cluster permutation test (see below, the yellow points in Figure 4F).
3 We also confirmed the difference between the tVNS and sham conditions using a post-hoc
4 direct comparison on the electrodes marked in blue in Figure 4A, using Wilcoxon signed rank
5 tests (Results).

6 **Statistical Analyses**

7 Unless stated otherwise, all statistical tests were carried out using a Wilcoxon signed rank test
8 (Wilcoxon, 1945). This included the significance of the pupil time-course, which was corrected
9 for multiple comparisons using FDR correction (Benjamini and Yekutieli, 2011). The
10 significance for alpha attenuation in the EEG spectrogram was assessed using a cluster
11 permutation test with the Monte Carlo method and a dependent samples T-statistic with 10,000
12 permutations, as implemented in the fieldtrip toolbox (Oostenveld et al., 2011). An alpha of
13 0.05 was considered significant after FDR correction for clusters (Benjamini and Yekutieli,
14 2011). In Figure 4, we plotted alpha attenuation at the individual participant level, to facilitate,
15 for the reader, the assessment of effect size across participants; these per-subject values were
16 also tested using the Wilcoxon signed rank test (Figure 4C). Data are expressed as mean \pm
17 standard error of the mean throughout.

1 Results

2 To investigate the short-term effects of tVNS in naïve humans, we compared pupil dynamics
3 and EEG alpha oscillations in healthy young male volunteers (n=24) induced by multiple trials
4 of short (3.4s) electrical stimulation at the cymba conchae (tVNS) and at the earlobe (sham)
5 (Figure 1). Stimulation was applied at a frequency of 25Hz, with the intensity ramping up
6 during the trial, to a maximal value selected per participant and location (Methods).

7 First, we verified that the sham and tVNS conditions did not differ in any of the parameters of
8 subjective averseness examined. Indeed, we did not find any significant differences between
9 the tVNS and sham conditions in subjective reports such as pain and irritation (Table 1, $P > 0.05$
10 for all comparisons after FDR correction). Regarding objective current intensity, the mean
11 values of the currents applied were 2.20 ± 0.24 mA in the tVNS condition and 2.79 ± 0.27 mA in
12 the sham condition. The higher current intensity in the sham condition was statistically
13 significant ($p = 0.0125$ Wilcoxon signed rank test). This is likely due to lower sensitivity at the
14 earlobe, and “works against” our a-priori hypothesis (larger effects in tVNS *despite* higher
15 current intensity in sham, see Discussion). This finding shows that earlobe stimulation provides
16 good somatosensory control, which distills the changes related specifically to tVNS.

17 **Table 1: Subjective ratings of tVNS/sham stimulation**

	tVNS	sham
I have a headache	1.82 ± 0.20	1.89 ± 0.22
I feel nausea	1.67 ± 0.19	1.63 ± 0.19
I feel dizziness	1.82 ± 0.22	1.97 ± 0.25
I feel neck pain	1.87 ± 0.16	1.97 ± 0.19
I feel muscle contraction in the neck	2.10 ± 0.20	2.00 ± 0.21
I feel stinging under the electrode	2.22 ± 0.22	2.18 ± 0.23
I feel skin irritation in the ear	2.17 ± 0.28	2.15 ± 0.27
I feel fluctuation in concentration	4.02 ± 0.39	3.73 ± 0.36
I have an unpleasant feeling	2.52 ± 0.29	2.71 ± 0.31
I am in a good mood	4.82 ± 0.32	5.23 ± 0.27
I am alert	4.07 ± 0.32	4.15 ± 0.31

1 **Transcutaneous vagus nerve stimulation induces pupil dilation**

2 tVNS led to robust pupil dilation that increased gradually (consistent with the ramping up of
3 the stimulation intensity), reaching half maximum at 2.53s after stimulation onset, peaking at
4 4.25s after stimulation onset, decreasing back to half maximum at 8.17s, and returning to
5 baseline levels 10s after stimulation. During peak pupil dilation, mean pupil size (in pixels) was
6 $4.05 \pm 0.92\%$ above baseline (Figure 2A).


7 In contrast, sham stimulation led to only modest pupil dilation, mean $1.67 \pm 0.63\%$, and peaking
8 around the same time. This dilation level was significantly weaker than following tVNS ($p < 0.05$
9 between 2.88-5.96s, repeated Wilcoxon signed rank test across all time points, and FDR
10 correction for multiple comparisons, red bar, Figure 2A). These results were largely consistent
11 across individual participants (Figure 2B) and evident in most (21 of 24) participants (for
12 examples see Figure 2C).

13 Baseline pupil values did not differ significantly between the tVNS and sham conditions ($p =$
14 0.5). In both conditions, the smaller the pupil before a specific trial, the higher the stimulation-
15 evoked response (Pearson's correlation $R = -0.27$, $p < 10^{-20}$). We found no significant differences
16 between the conditions, in blink rate or gaze position ($p > 0.6$ for all comparisons, using the same
17 statistical procedure). In addition, the higher pupil dilation upon tVNS remained significant and
18 robust across individuals, when the blink data were discarded (rather than interpolated). To
19 verify that the effect of pupil dilation was not mediated by the difference in objective currents,
20 we calculated the correlation between differences in pupil dilation (across the tVNS and sham
21 conditions), and the difference in current (across the tVNS and sham conditions). This did not
22 reveal a significant correlation (Spearman correlation $R = -0.12$, $p = 0.56$).

23 In a pilot experiment that employed 30s ON / 30s OFF 'clinical-like' stimulation, we observed
24 only a modest trend for greater pupil dilation for tVNS than sham stimulation ($p = 0.053$, $n = 23$),
25 and pupil size did not differ significantly between ON and OFF periods. Thus, short tVNS
26 pulses lead to significantly greater pupil dilation than following sham stimulation. This

1 indicates that tVNS promotes arousal above and beyond somatosensory stimulation at the ear.

2 **Figure 2: tVNS leads to greater pupil dilation than sham stimulation**



3

4 **Legend:** (A) Grand average pupil dilation in response to tVNS (red trace) and sham stimulation
5 (black trace). Shaded areas around the trace indicate the standard error of the mean. The grey
6 transparent rectangle indicates that the active current is on. The upper red line indicates FDR-
7 corrected statistical significance using the Wilcoxon signed rank test. The dashed black bar
8 indicates the time interval used to compute individual subject dilation values in B. (B) Single
9 participant values in both tVNS and sham conditions between the 2 points of half maximum
10 (FDHM, 3.2-10.4s dashed black bar in A). The solid black lines denote tVNS>sham, while the
11 dashed grey lines denote sham>tVNS. I,II refers to the single participant traces shown in C. (C)
12 Two representative single-subject pupil time-courses as indicated in B, with identical graphic
13 representation as in A.


14

15 **Transcutaneous vagus nerve stimulation attenuates alpha oscillations**

16 Alpha oscillations exhibit considerable inter-individual variability in frequency and scalp
17 topography (Haegens et al., 2014). To discern the effects of tVNS and sham stimulation on
18 alpha activity, we first identified the frequency and topography of alpha oscillations in each
19 participant separately, using PARAFAC analysis (Harshman, 1970). PARAFAC provides a
20 unique solution for decomposing the EEG signal to three factors (time, frequency, channel;

1 Figure 3A) and may enhance sensitivity. This analytic technique was previously applied to
2 electrophysiological recordings (Miwakeichi et al., 2004; Yanagawa et al., 2013; Meij et al.,
3 2016), and specifically to assessing individual alpha oscillations (Barzegaran et al., 2017;
4 Knyazeva et al., 2018); for a detailed review of its EEG applications, see Cong et al (2015). We
5 identified the regions and frequencies of interest for alpha oscillations in each participant
6 separately, using unbiased “break” data between stimulation blocks (Figure 3B). Figure 3C,D
7 presents the result of this process in representative participants, and Figure 4A shows the
8 median region and frequency profile of alpha oscillations across all participants. PARAFAC
9 successfully identified alpha activity (see the examples in Figure 3C,D), capturing each
10 individual's specific alpha frequency around 7-13Hz, with the typical occipital topography.

11 **Figure 3: Parallel Factor Analysis (PARAFAC) to identify individual alpha activity**



12

13 **Legend:** Graphic illustration of the Parallel Factor Analysis (PARAFAC) method we used to
14 decompose the stimulus-free (break) data and create subject-specific topographical and
15 frequency bands of interest. (A) Illustration of the PARAFAC model with two components, in
16 which f_1 and f_2 refer to the frequency features, t_1 and t_2 indicate temporal features, and c_1 and
17 c_2 represent the spatial features of the components in the channel space. (B) Spectrogram of
18 five single 3s "trials" derived from the break, the same subject as in the top left in C. (C,D)
19 Representative examples of the decomposition result for two participants. Each panel includes

1 two components: 1 (pink), and 2 (blue), together with their associated frequency (f) and trial (t)
2 profiles. The spatial (channel) dimension is presented as scalp topographies on the right side.
3 After identifying alpha activity for each individual, we quantified the extent that this activity
4 may be decreased by tVNS or sham stimulation in each participant separately. We found that
5 tVNS attenuated alpha activity (mean: $94.35 \pm 2.2\%$ of baseline) to a greater extent ($p=0.0027$,
6 Wilcoxon signed rank test) than did sham stimulation, which was not associated with significant
7 alpha attenuation (mean: $103.55 \pm 2.4\%$ of baseline). Baseline alpha was not significantly
8 different between the conditions ($p = 0.3$ via the Wilcoxon signed rank test). Greater alpha
9 attenuation following tVNS was evident in most (19/21) participants (Figure 4B).

10 We found a significant negative correlation between the differences in alpha attenuation (tVNS
11 vs. sham conditions) in each individual and the differences in applied current (tVNS vs. sham
12 conditions) (Spearman correlation $R=-0.49$, $p=0.02$). Accordingly, participants with stronger
13 sham stimulation current showed less difference in alpha attenuation. Along this line, we
14 repeated the analysis for alpha attenuation while removing one third of the participants with the
15 highest difference in current between the conditions. This analysis revealed a difference in
16 alpha attenuation that was even more significant for the remaining 14 participants, despite the
17 fewer number of participants ($p=0.0001$, Wilcoxon signed rank test). The implication is that the
18 alpha attenuation we observed upon tVNS constitutes a lower bound (an equivalent objective
19 current intensity in the two conditions leads to a stronger difference in alpha attenuation
20 between the tVNS and sham conditions, see also Discussion).”

21

22


23

24

25

26

1 **Figure 4: tVNS leads to greater attenuation of EEG alpha activity than does the sham**
2 stimulation



3

4 Legend: (A) Median alpha component topography. The median weights across participants are
5 colored pink. The blue points mark electrodes with the highest alpha activity (selected using a
6 threshold applied to the median weights) to facilitate visualization in subsequent panel E, but
7 these electrodes are not used in any statistical analyses. (B) Alpha attenuation relative to
8 baseline in individual subject data between 0:4sec, using the weighted topography in A and
9 using the spectral profile in C. Black solid lines mark participants with higher alpha decreases
10 in the tVNS condition (19/21), whereas dashed gray lines mark participants with higher alpha
11 decreases in the sham condition (2/21). (C) Alpha component spectral profile (median across
12 participants). (D) The mean alpha component time-course (using the spectral profile depicted
13 in C, and the topographical profile depicted in A). (E) The difference in induced power between
14 the tVNS and sham conditions (shown separately in G and H). White contours mark statistically
15 significant time-frequency clusters (after correction for multiple comparisons). Note that tVNS
16 causes alpha attenuation lasting several seconds. (F) Topographical dynamics following
17 stimulation (at a resolution of 1s) reveals occipital alpha attenuation upon tVNS (upper panel)
18 but not in the sham condition (lower panel). The yellow points mark electrodes comprising the
19 statistically significant time-space cluster that exhibits tVNS attenuation > sham
20 attenuation (after correction for multiple comparisons). (G) Mean induced spectrogram upon
21 tVNS; the white contour is identical to that shown in E. (H) The mean induced spectrogram
22 upon sham stimulation; the white contour is identical to that shown in E.

23

24 tVNS-induced alpha attenuation was not observed in our pilot experiment, which employed 30s

25 ON / 30s OFF 'clinical-like' stimulation ($p > 0.05$, $n=15$). Neither experiment revealed a

1 significant correlation between alpha attenuation and individual subjective (or objective) scores
2 of stimulation intensities, nor a significant correlation between alpha attenuation and pupil
3 dilation at the individual level (all $p \geq 0.1$).

4 To complement the PARAFAC-based analysis and to better understand the precise time-
5 frequency dynamics and topographical changes of alpha attenuation, we used the weighted
6 alpha topography from the break data as a ‘weighted region of interest’. This reduced the data
7 to two dimensions (time and frequency). Such approach ignored the frequency-of-interest and
8 inspected the induced power changes in the 5-15Hz frequency range for the (weighted) occipital
9 region derived from the PARAFAC decomposition (Figure 4A). In line with the previous
10 results, we found that tVNS significantly attenuated activity in the alpha band (8-12Hz, Figure
11 4G). Similarly, examining the effects of stimulation on EEG dynamics using cluster based
12 permutation (Maris and Oostenveld, 2007) revealed a significant ($p=0.0063$, white contour in
13 Figure 4G-H) cluster around 8-12Hz in the seconds following stimulation onset. During this
14 time interval, the mean alpha power was $90.84 \pm 2.77\%$ in the tVNS condition, significantly
15 lower than the mean $106.66 \pm 2.70\%$ observed in the sham condition ($p < 0.0001$ in a direct
16 comparison). We also compared the two conditions using the classical alpha frequency range
17 (8-12Hz), during stimulation (0-4s) (means: $94.41 \pm 2.15\%$ in the tVNS condition and
18 $105.25 \pm 2.41\%$ in the sham condition, $p=0.0012$ (the Wilcoxon signed rank test for both)).

19 Finally, we examined the extent that the observed alpha attenuation was specific to occipital
20 electrodes. We inspected the topographical changes in voltage around stimulation relative to
21 baseline (Figure 4F). This analysis was carried out by focusing on the a-priori frequency-band
22 of interest derived from the PARAFAC decomposition (Figure 4C), while ignoring the
23 topography-of-interest derived from the break. We examined topographical effects of
24 stimulation on EEG dynamics using topographical cluster-based permutation (Maris and
25 Oostenveld, 2007). This revealed a significant ($p < 0.05$) cluster over occipital electrodes, which
26 exhibited tVNS attenuation $>$ sham attenuation (yellow points in Figure 4F). The implication
27 is that alpha attenuation was specific to occipital areas (the mean attenuation in yellow

1 electrodes in Figure 4F, during 0:4sec: $-3.75\mu\text{V}$ and $-1.78\mu\text{V}$ in the tVNS and sham conditions,
2 respectively, $p=0.007$ via the Wilcoxon signed rank test). We also compared the two conditions
3 directly using the occipital electrodes marked in Figure 4A, during 0:4sec (mean: $3.75\mu\text{V}$ and
4 $-1.78\mu\text{V}$ in the respective conditions, $p=0.007$ via the Wilcoxon signed rank test). Importantly,
5 the regions showing tVNS-induced alpha attenuation overlapped electrodes showing alpha
6 activity in the independent “break” intervals between stimulation blocks (compare the blue dots
7 in Figure 4A with the yellow dots in Figure 4F).

8 Altogether, the EEG data establish that short tVNS pulses, but not sham stimulation, attenuate
9 occipital alpha activity.

1 **Discussion**

2 We examined the effects of short tVNS pulses (and sham stimulation at the ear lobe) on pupil
3 dynamics and EEG alpha activity in naïve healthy men. While subjective stimulation intensities
4 were not significantly different in the two conditions (Table 1), we found that short tVNS pulses
5 induce pupil dilation (Figure 2) and EEG alpha attenuation (Figure 4) to a greater extent than
6 does sham stimulation. These effects support the hypothesis that tVNS activates endogenous
7 arousal-promoting neuromodulatory signaling such as LC-NE activity, as is known to occur in
8 invasive VNS (Hulseley et al., 2017; Mridha et al., 2019). This suggests that tVNS mimics VNS.

9 **Validity and limitations.** Our results were obtained during fixation at rest. Although they may
10 be applicable to other conditions, future studies are needed to determine the effects of short-
11 pulse tVNS during other states, such as drowsiness and sleep, and during the performance of
12 specific cognitive tasks. For example, high arousal at baseline could create a ceiling effect for
13 pupil dilation and alpha attenuation; conversely, during decreased vigilance, EEG effects may
14 attenuate idle activity at different frequency bands (e.g. changing the theta/alpha ratio during
15 drowsiness, or suppressing slow wave activity in sleep). Another limitation is that we could
16 only study tVNS in male volunteers. Since there may be sex-specific differences in LC-NE and
17 neuromodulatory activity (Bangasser et al., 2016), future studies with females are warranted.
18 Lastly, our experimental design equated the subjective intensity of tVNS and sham stimulation.
19 Our data revealed that a significantly higher current at the earlobe (sham condition) was
20 necessary to achieve equal subjective intensity. We did not find a significant correlation
21 between differences in current (tVNS vs. sham) and in pupil dilation (tVNS vs. sham), but
22 current differences were negatively correlated with differences in alpha attenuation (tVNS vs.
23 sham). Accordingly, among participants with a higher current intensity in the sham than the
24 tVNS condition, the difference in alpha attenuation was smaller between the conditions. Indeed,
25 restricting the analysis to a subset of 14 individuals, such that the significant difference in
26 current intensity was eliminated, revealed a stronger effect of alpha attenuation in the tVNS vs.
27 sham condition. Thus, our results represent a conservative lower-bound of the actual difference

1 between alpha attenuation in tVNS and sham, which would be even greater in the context of
2 comparable currents in tVNS and sham. More generally, this issue is relevant to an inherent
3 limitation of using earlobe sham stimulation as a control condition. Despite its extensive use
4 (Yap et al., 2020) and advantages, the earlobe, with its lower sensitivity, requires higher
5 currents to produce a comparable subjective intensity. Future studies should apply additional
6 control conditions (e.g. stimulation at other frequencies) to mitigate this limitation.

7 **Previous tVNS studies.** Our finding that tVNS attenuates alpha oscillations is compatible with
8 the findings of a number of studies (Bodin et al., 2015; Lewine et al., 2019); while earlier studies
9 reported mixed results or did not detect EEG effects (Hammond et al., 1992; Salinsky and
10 Burchiel, 1993). Our use of short tVNS pulses likely contributed to our ability to reveal alpha
11 attenuation. In addition, the sensitive analysis that was afforded by the use of PARAFAC
12 enabled identifying alpha effects in many, but not all the participants.

13 In contrast to our focus on ongoing EEG and pupillometry, most previous studies attempted to
14 demonstrate the effectiveness of tVNS by focusing on the EEG P300 or on salivary alpha
15 amylase as readouts. The P300 is a positive deflection with maximal amplitude in electrodes
16 placed over the centro-parietal midline, 300-500ms after stimulus onset. The amplitude of this
17 deflection is modulated by the probability of stimulus appearance regardless of sensory
18 modality (Desmedt et al., 1965; Sutton et al., 1965). The P300 has been hypothesized to be a
19 marker of LC-NE activity (Nieuwenhuis et al., 2005). This is because LC neurons are likewise
20 activated by infrequent stimuli, independent of sensory modality (Aston-Jones et al., 1991); and
21 deviant stimuli elicit greater pupil dilation than standard stimuli (Murphy et al., 2011).
22 However, the P300 may not constitute a straightforward test of tVNS efficacy since the link
23 between P300 and LC-NE activity is still debated (Nieuwenhuis et al., 2011), and the
24 dopaminergic (Glover et al., 1988) and glutamatergic (Hall et al., 2015) systems could also
25 substantially affect the P300. Ventura-Bort et al (2018) demonstrated that tVNS amplifies the
26 parietal component of the P300 effect (P3b), selectively, for easy targets in their task. However,
27 this effect was modest and could not be replicated using weaker fixed currents (0.5mA) and a

1 simpler classical P300 task (Warren et al., 2018). Another study by Keute et al (2019) focused
2 on the difference in pupil dilation between deviant and standard stimuli, using a classical
3 auditory oddball task. The use of a constant 3mA tVNS in all participants did not reveal any
4 effect of the stimulation on event-related or baseline pupil size. A possible explanation is that
5 30s tVNS modulates tonic NE levels but does not affect phasic stimulus-evoked changes in NE
6 that are associated with the P300. In agreement with this possibility, the use of clonidine (an α 2
7 adrenergic receptor agonist that reduces NE signaling) provided similar mixed results (Pineda
8 and Swick, 1992; Halliday et al., 1994; Pineda et al., 1997; Brown et al., 2015). Future studies
9 that will use short tVNS pulses, as used here, may help elucidate the effects on the P300.

10 Both Warren et al (Warren et al., 2018) and Ventura-Bort (2018) showed that tVNS increases
11 levels of salivary alpha amylase, which has served as a peripheral measure of sympathetic
12 activity associated with LC-NE signaling (Rohleder and Nater, 2009). However, this measure
13 has poor temporal resolution and can only reveal differences between time intervals before vs.
14 after stimulation blocks that last several minutes. This approach does not leverage the superior
15 temporal resolution of tVNS compared to pharmacological manipulations of NE in humans;
16 such manipulations are highly effective in studying the effects of slower NE dynamics
17 (Gelbard-Sagiv et al., 2018). By contrast, the transient (within seconds) tVNS-mediated effects
18 revealed here offer considerable advantages over the slow modulations elicited by NE drugs.

19 **Pupil dilation and alpha attenuation as indices of arousal and LC-NE activity.** Pupil
20 diameter was suggested as a proxy for noradrenergic signaling since Aston Jones and Cohen
21 first provided an example of correlated dynamics in simultaneous pupil and LC single-unit
22 activities in a monkey (Aston-Jones and Cohen, 2005; and see a recent review by Joshi and
23 Gold, 2020). Since this initial report, the relation between pupil diameter and noradrenergic
24 signaling has been established in monkeys (Varazzani et al., 2015; Joshi et al., 2016), rats (Liu
25 et al., 2017; Hayat et al., 2020), and mice (Reimer et al., 2016; Breton-Provencher and Sur,
26 2019), as well as in human BOLD fMRI (Murphy et al., 2014). The tVNS-induced pupil dilation
27 time-course that we observed (Figure 3) resembles pupil dynamics in response to LC electrical

1 stimulation in monkeys (Joshi et al., 2016) and optogenetic stimulation in rats (Hayat et al.,
2 2020). This supports the hypothesis that tVNS activates the LC, as has been established for
3 invasive VNS.

4 Alpha oscillations are abundant during detachment from the sensory environment in
5 wakefulness. These are considered an index of low arousal (Torsvall and Akerstedt, 1987b;
6 Drapeau and Carrier, 2004b). Alpha oscillations are believed to represent an “idling” state of
7 cortical activity (Steriade, 2001; Palva and Palva, 2007) that is expected to be anti-correlated
8 with arousal-promoting activity, such as that of the LC-NE system. These oscillations bias
9 sensory perception (Waschke et al., 2019). A recent study that used long 2min tVNS on the
10 neck also found that tVNS attenuates alpha and theta oscillation (Lewine et al., 2019).

11 **LC-NE vs. other neuromodulatory systems.** While pupil dilation and EEG alpha attenuation
12 are both *compatible* with noradrenergic signaling, LC-NE involvement is unlikely to be the
13 only modulatory system involved, given the overlap and redundancy among neuromodulatory
14 systems. Other elements such as the cholinergic system also contribute to brain arousal and are
15 associated with both pupil dilation (Reimer et al., 2016) and EEG activation (Szerb, 1967).
16 However, cholinergic activation alone is unlikely to drive the effects observed. This is because
17 during rapid eye movement (REM) sleep, cholinergic activation occurs without LC-NE activity
18 (Nir and Tononi, 2010); and the EEG is activated but pupils remain constricted (Siegel, 2005).
19 Moreover, given that VNS robustly activates the LC, and no such relation has been reported for
20 cholinergic nuclei, the most parsimonious interpretation is that the primary neuromodulatory
21 effects of tVNS are noradrenergic, while cholinergic modulation (Mridha et al., 2019) is likely
22 secondary. tVNS may engage additional subcortical neuromodulatory systems such as the
23 dorsal raphe and the ventral tegmental area, as observed with tVNS-induced BOLD fMRI
24 (Frangos et al., 2015). Thus, the possible relation of tVNS to other neuromodulatory systems
25 beyond LC-NE is an important topic for further investigation.

26 **tVNS as a novel tool for transient neuromodulation.** Great interest has arisen in investigating
27 the contribution of the LC-NE system to human cognition, including perception, learning and

1 memory, decision-making, and aging and neurodegeneration. In this context, tVNS entails
2 important advantages over existing tools. While important advances have been made by relying
3 on the correlation of LC-NE activity with pupil dynamics (e.g de Gee et al., 2017), hidden
4 factors (such as fluctuations in arousal and attention) could be at the basis of the observed
5 correlations (Clewett et al., 2018; Dragone et al., 2018). Previous human studies also employed
6 *causal* perturbations, using NE drugs to study effects on perception (Gelbard-Sagiv et al.,
7 2018), memory (see van Stegeren, 2008 for review), and decision making (Warren et al., 2017).
8 However, the systemic delivery of NE drugs is inherently limited to affecting tonic LC-NE
9 activity and has poor temporal resolution, whereas tVNS has clear added value.

10 A number of studies reported a benefit of invasive VNS on memory (Clark et al., 1999; Jacobs
11 et al., 2015; for review see Hansen, 2017; Sun et al., 2017). However, the participants of those
12 studies had severe epilepsy or depression. In addition, ongoing daily VNS induces complex
13 long-term plastic changes that make interpretation difficult.

14 Due to limitations of the available techniques for studying cognition, the potential of tVNS has
15 been recognized and is increasingly being realized (Van Leusden et al., 2015). However, to
16 date, the evidence supporting the effectiveness of tVNS in mimicking invasive VNS is mixed.
17 We applied short stimulation pulses and limited currents to a maximal value per participant.
18 Accordingly, and by focusing on simple pupillary and ongoing EEG readouts, we showed that
19 tVNS transiently elicits markers of brain arousal that are compatible with arousal-promoting
20 neuromodulatory signaling such as NE/Ach. This supports the hypothesis that tVNS mimics
21 invasive VNS, thereby extending the experimental toolkit for non-pharmacological
22 neuromodulation in humans with high temporal resolution. Therefore, tVNS can be used to
23 further investigate the means by which transient neuromodulation contributes to human
24 cognition. Future studies should compare several levels of both sham stimulation and tVNS, to
25 conduct a parametric investigation. Of note, stronger stimulation may not necessarily produce
26 stronger effects on neuronal activity and behavior, since some effects may actually elicit “U-
27 shape” profiles (for example see Clark et al., 1999).

1 Finally, tVNS should be conducted to further elucidate the processes mediating the clinical
2 improvements elicited by VNS in epilepsy and depression. These include the role of arousal-
3 promoting neuromodulatory signaling in improving mood in depressed patients (Grimonprez
4 et al., 2015; Liu et al., 2016; Fang et al., 2017; Tu et al., 2018). In particular, tVNS-induced
5 pupillary and EEG effects may help predict clinical efficacy of invasive VNS and thus facilitate
6 triaging patients to receive either conservative therapy or surgical implantation of VNS
7 stimulation devices.

8 **Software Accessibility** code is available upon request.

9 **Acknowledgements:** Supported by ISF 51/11 (I-CORE cognitive sciences) and the Adelis
10 Foundation (YN), The Herczeg Institute on Aging, the TAU global research fund, and the
11 Naomi Foundation (OS). The authors thank members of the Nir lab for discussions, and Leon
12 Deouell and Amit Marmelshtein for their comments on earlier drafts of the manuscript.

1 **References**

- 2 Amzica F, Lopes da Silva FH (2017) Niedermeyer's Electroencephalography (Schomer DL,
3 Lopes da Silva FH, eds). Oxford University Press. Available at:
4 [http://www.oxfordmedicine.com/view/10.1093/med/9780190228484.001.0001/med-](http://www.oxfordmedicine.com/view/10.1093/med/9780190228484.001.0001/med-9780190228484)
5 [9780190228484](http://www.oxfordmedicine.com/view/10.1093/med/9780190228484.001.0001/med-9780190228484).
- 6 Andersson CA, Bro R (2000) The N -way Toolbox for MATLAB. :3–6.
- 7 Aston-Jones G, Chiang C, Alexinsky T (1991) Discharge of noradrenergic locus coeruleus
8 neurons in behaving rats and monkeys suggests a role in vigilance. *Prog Brain Res*
9 *88:501–520* Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1813931>.
- 10 Aston-Jones G, Cohen JD (2005) An integrative theory of locus coeruleus-norepinephrine
11 function: adaptive gain and optimal performance. *Annu Rev Neurosci* *28:403–450*
12 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16022602>.
- 13 Badran BW, Brown JC, Dowdle LT, Mithoefer OJ, LaBate NT, Coatsworth J, DeVries WH,
14 Austelle CW, McTeague LM, Yu A, Bikson M, Jenkins DD, George MS (2018) Tragus
15 or cymba conchae? Investigating the anatomical foundation of transcutaneous auricular
16 vagus nerve stimulation (taVNS). *Brain Stimul* *11:947–948* Available at:
17 <https://doi.org/10.1016/j.brs.2018.06.003>.
- 18 Bangasser DA, Wiersielis KR, Khantsis S (2016) Sex differences in the locus coeruleus-
19 norepinephrine system and its regulation by stress. *Brain Res* *1641:177–188* Available
20 at: <http://www.ncbi.nlm.nih.gov/pubmed/26607253>.
- 21 Barzegaran E, Vildavski VY, Knyazeva MG (2017) Fine Structure of Posterior Alpha
22 Rhythm in Human EEG : Frequency Components , Their Cortical Sources , and
23 Temporal Behavior. :1–12.
- 24 Bauer S, Baier H, Baumgartner C, Bohlmann K, Fauser S, Graf W, Hillenbrand B, Hirsch M,
25 Last C, Lerche H, Mayer T, Schulze-Bonhage A, Steinhoff BJ, Weber Y, Hartlep A,
26 Rosenow F, Hamer HM (2016) Transcutaneous Vagus Nerve Stimulation (tVNS) for

- 1 Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial
2 (cMPsE02). *Brain Stimul* 9:356–363 Available at:
3 <http://dx.doi.org/10.1016/j.brs.2015.11.003>.
- 4 Benjamini Y, Yekutieli D (2011) The Control of the False Discovery Rate in Multiple Testing
5 under Dependency Source. *Statistics (Ber)* 29:1165–1188.
- 6 Bermejo P, López M, Larraya I, Chamorro J, Cobo JL, Ordóñez S, Vega JA (2017)
7 Innervation of the Human Cavum Conchae and Auditory Canal : Anatomical Basis for
8 Transcutaneous Auricular Nerve Stimulation. 2017.
- 9 Bodin C, Aubert S, Daquin G, Carron R, Scavarda D, McGonigal A, Bartolomei F (2015)
10 Responders to vagus nerve stimulation (VNS) in refractory epilepsy have reduced
11 interictal cortical synchronicity on scalp EEG. *Epilepsy Res* 113:98–103 Available at:
12 <http://dx.doi.org/10.1016/j.eplepsyres.2015.03.018>.
- 13 Boon P, De Cock E, Mertens A, Trinka E (2018) Neurostimulation for drug-resistant
14 epilepsy. *Curr Opin Neurol* 31:198–210 Available at:
15 <http://insights.ovid.com/crossref?an=00019052-201804000-00015>.
- 16 Breton-Provencher V, Sur M (2019) Active control of arousal by a locus coeruleus
17 GABAergic circuit. *Nat Neurosci* 22:218–228 Available at:
18 <http://www.ncbi.nlm.nih.gov/pubmed/30643295>.
- 19 Bro R, Kiers HAL (2003) A new efficient method for determining the number of components
20 in PARAFAC models. *J Chemom* 17:274–286 Available at:
21 <http://doi.wiley.com/10.1002/cem.801>.
- 22 Brown SBRE, van der Wee NJA, van Noorden MS, Giltay EJ, Nieuwenhuis S (2015)
23 Noradrenergic and cholinergic modulation of late ERP responses to deviant stimuli.
24 *Psychophysiology* 52:1620–1631 Available at:
25 <http://doi.wiley.com/10.1111/psyp.12544>.
- 26 Clark KB, Naritoku DK, Smith DC, Browning RA, Jensen RA (1999) Enhanced recognition

- 1 memory following vagus nerve stimulation in human subjects. *Nat Neurosci* 2:94–98
2 Available at: <http://www.nature.com/doi/10.1038/4600>.
- 3 Clewett D V., Huang R, Velasco R, Lee T-H, Mather M (2018) Locus Coeruleus Activity
4 Strengthens Prioritized Memories Under Arousal. *J Neurosci* 38:1558–1574 Available
5 at: <http://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.2097-17.2017>.
- 6 Cong F, Lin Q, Kuang L, Gong X, Astikainen P (2015) Tensor decomposition of EEG
7 signals : A brief review. *J Neurosci Methods* 248:59–69 Available at:
8 <http://dx.doi.org/10.1016/j.jneumeth.2015.03.018>.
- 9 de Gee JW, Colizoli O, Kloosterman NA, Knapen T, Nieuwenhuis S, Donner TH (2017)
10 Dynamic modulation of decision biases by brainstem arousal systems. *Elife* 6 Available
11 at: <http://www.ncbi.nlm.nih.gov/pubmed/28383284>.
- 12 Desbeaumes Jodoin V, Lespérance P, Nguyen DK, Fournier-Gosselin M-PP, Richer F (2015)
13 Effects of vagus nerve stimulation on pupillary function. *Int J Psychophysiol* 98:455–
14 459 Available at: <http://dx.doi.org/10.1016/j.ijpsycho.2015.10.001>.
- 15 Desmedt JE, Debecker J, Manil J (1965) [Demonstration of a cerebral electric sign associated
16 with the detection by the subject of a tactile sensorial stimulus. The analysis of cerebral
17 evoked potentials derived from the scalp with the aid of numerical ordinates]. *Bull Acad*
18 *R Med Belg* 5:887–936 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/5864251>.
- 19 Dorr AE, Debonnel G (2006) Effect of Vagus Nerve Stimulation on Serotonergic and
20 Noradrenergic Transmission. 318:890–898.
- 21 Dragone A, Lasaponara S, Pinto M, Rotondaro F, De Luca M, Doricchi F (2018) Expectancy
22 modulates pupil size during endogenous orienting of spatial attention. *Cortex* 102:57–66
23 Available at: <https://linkinghub.elsevier.com/retrieve/pii/S0010945217303179>.
- 24 Drapeau C, Carrier J (2004a) Fluctuation of waking electroencephalogram and subjective
25 alertness during a 25-hour sleep-deprivation episode in young and middle-aged subjects.
26 *Sleep* 27:55–60 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14998238>.

- 1 Drapeau C, Carrier J (2004b) Fluctuation of waking electroencephalogram and subjective
2 alertness during a 25-hour sleep-deprivation episode in young and middle-aged subjects.
3 Sleep 27:55–60.
- 4 Ellrich J (2011) Transcutaneous Vagus Nerve Stimulation. Eur Neurol Rev 6:254 Available
5 at: <http://www.touchneurology.com/articles/transcutaneous-vagus-nerve-stimulation>.
- 6 Fang J, Egorova N, Rong P, Liu J, Hong Y, Fan Y, Wang X, Wang H, Yu Y, Ma Y, Xu C, Li
7 S, Zhao J, Luo M, Zhu B, Kong J (2017) Early cortical biomarkers of longitudinal
8 transcutaneous vagus nerve stimulation treatment success in depression. NeuroImage
9 Clin 14:105–111 Available at: <http://dx.doi.org/10.1016/j.nicl.2016.12.016>.
- 10 Follesa P, Biggio F, Gorini G, Caria S, Talani G, Dazzi L, Puligheddu M, Marrosu F, Biggio
11 G (2007) Vagus nerve stimulation increases norepinephrine concentration and the gene
12 expression of BDNF and bFGF in the rat brain. 79.
- 13 Frangos E, Ellrich J, Komisaruk BR (2015) Non-invasive access to the vagus nerve central
14 projections via electrical stimulation of the external ear: FMRI evidence in humans.
15 Brain Stimul 8:624–636 Available at: <http://dx.doi.org/10.1016/j.brs.2014.11.018>.
- 16 Gelbard-Sagiv H, Magidov E, Sharon H, Hendler T, Nir Y (2018) Noradrenaline Modulates
17 Visual Perception and Late Visually Evoked Activity. Curr Biol 28:2239-2249.e6
18 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/29983318>.
- 19 Glover A, Ghilardi MF, Bodis-Wollner I, Onofri M (1988) Alterations in event-related
20 potentials (ERPs) of MPTP-treated monkeys. Electroencephalogr Clin Neurophysiol
21 Potentials Sect 71:461–468 Available at:
22 <https://linkinghub.elsevier.com/retrieve/pii/0168559788900500>.
- 23 Grimonprez A et al. (2015) The antidepressant-like effect of vagus nerve stimulation is
24 mediated through the locus coeruleus. J Psychiatr Res 68:1–7 Available at:
25 <http://dx.doi.org/10.1016/j.jpsychires.2015.05.002>.
- 26 Groves DA, Bowman EM, Brown VJ (2005) Recordings from the rat locus coeruleus during

- 1 acute vagal nerve stimulation in the anaesthetised rat. *Neurosci Lett* 379:174–179.
- 2 Haegens S, Cousijn H, Wallis G, Harrison PJ, Nobre AC (2014) Inter- and intra-individual
3 variability in alpha peak frequency. *Neuroimage* 92:46–55 Available at:
4 <http://dx.doi.org/10.1016/j.neuroimage.2014.01.049>.
- 5 Hall M-H, Jensen JE, Du F, Smoller JW, O'Connor L, Spencer KM, Öngür D (2015) Frontal
6 P3 event-related potential is related to brain glutamine/glutamate ratio measured in vivo.
7 *Neuroimage* 111:186–191 Available at:
8 <https://linkinghub.elsevier.com/retrieve/pii/S1053811915001159>.
- 9 Halliday R, Naylor H, Brandeis D, Callaway E, Yano L, Herzig K (1994) The effect of D-
10 amphetamine, clonidine, and yohimbine on human information processing.
11 *Psychophysiology* 31:331–337.
- 12 Hammond EJ, Uthman BM, Reid SA, Wilder BJ (1992) Electrophysiological Studies of
13 Cervical Vagus Nerve Stimulation in Humans: I. EEG Effects. *Epilepsia* 33:1013–1020.
- 14 Hansen N (2017) The Longevity of Hippocampus-Dependent Memory Is Orchestrated by the
15 Locus Coeruleus-Noradrenergic System. *Neural Plast* 2017.
- 16 Harshman RA (1970) Foundations of the PARAFAC procedure: Models and conditions for
17 an "explanatory" multimodal factor analysis.
- 18 Hayat H, Regev N, Matosevich N, Sales A, Paredes-Rodriguez E, Krom AJ, Bergman L, Li
19 Y, Lavigne M, Kremer EJ, Yizhar O, Pickering AE, Nir Y (2020) Locus coeruleus
20 norepinephrine activity mediates sensory-evoked awakenings from sleep. *Sci Adv*
21 6:eaaz4232 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/32285002>.
- 22 He W, Jing X-H, Zhu B, Zhu X-L, Li L, Bai W-Z, Ben H (2013) The auriculo-vagal afferent
23 pathway and its role in seizure suppression in rats. *BMC Neurosci* 14:85 Available at:
24 <http://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-14-85>.
- 25 Hein E, Nowak M, Kiess O, Biermann T, Bayerlein K, Kornhuber J, Kraus T (2013)

- 1 Auricular transcutaneous electrical nerve stimulation in depressed patients: A
2 randomized controlled pilot study. *J Neural Transm* 120:821–827.
- 3 Hulsey DR, Riley JR, Loerwald KW, Li RLR, Kilgard MP, Hays SA (2017) Parametric
4 characterization of neural activity in the locus coeruleus in response to vagus nerve
5 stimulation. *Exp Neurol* 289:21–30 Available at:
6 <http://dx.doi.org/10.1016/j.expneurol.2016.12.005>.
- 7 Jacobs HIL, Riphagen JM, Razat CM, Wiese S, Sack AT (2015) Transcutaneous vagus nerve
8 stimulation boosts associative memory in older individuals. *Neurobiol Aging* 36:1860–
9 1867.
- 10 Joshi S, Gold JI (2020) Pupil Size as a Window on Neural Substrates of Cognition. *Trends*
11 *Cogn Sci* 24:466–480 Available at:
12 <https://linkinghub.elsevier.com/retrieve/pii/S1364661320300802>.
- 13 Joshi S, Li Y, Kalwani RM, Gold JI (2016) Relationships between Pupil Diameter and
14 Neuronal Activity in the Locus Coeruleus, Colliculi, and Cingulate Cortex. *Neuron*
15 89:221–234 Available at:
16 <https://linkinghub.elsevier.com/retrieve/pii/S089662731501034X>.
- 17 Keute M, Demirezen M, Graf A, Mueller NG, Zaehle T (2019) No modulation of pupil size
18 and event-related pupil response by transcutaneous auricular vagus nerve stimulation
19 (taVNS). *Sci Rep* 9:11452 Available at: [http://www.nature.com/articles/s41598-019-](http://www.nature.com/articles/s41598-019-47961-4)
20 47961-4.
- 21 Knyazeva MG, Barzegaran E, Vildavski VY, Demonet J (2018) Neurobiology of Aging of
22 human alpha rhythm. *Neurobiol Aging* 69:261–273 Available at:
23 <https://doi.org/10.1016/j.neurobiolaging.2018.05.018>.
- 24 Krahl SE, Clark KB (2012) Vagus nerve stimulation for epilepsy: A review of central
25 mechanisms. *Surg Neurol Int* 3:S255-9 Available at:
26 <http://www.ncbi.nlm.nih.gov/pubmed/23230530>.

- 1 Krahl SE, Clark KB, Smith DC, Browning RA (1998) Locus coeruleus lesions suppress the
2 seizure-attenuating effects of vagus nerve stimulation. *Epilepsia* 39:709–714.
- 3 Kraus T, Hösl K, Kiess O, Schanze A, Kornhuber J, Forster C (2007) BOLD fMRI
4 deactivation of limbic and temporal brain structures and mood enhancing effect by
5 transcutaneous vagus nerve stimulation. *J Neural Transm* 114:1485–1493.
- 6 Kraus T, Kiess O, Hösl K, Terekhin P, Kornhuber J, Forster C (2013) CNS BOLD fMRI
7 effects of sham-controlled transcutaneous electrical nerve stimulation in the left outer
8 auditory canal - A pilot study. *Brain Stimul* 6:798–804 Available at:
9 <http://dx.doi.org/10.1016/j.brs.2013.01.011>.
- 10 Kwon C-S, Ripa V, Al-Awar O, Panov F, Ghatan S, Jetté N (2018) Epilepsy and
11 Neuromodulation—Randomized Controlled Trials. *Brain Sci* 8:69 Available at:
12 <http://www.mdpi.com/2076-3425/8/4/69>.
- 13 Lewine JD, Paulson K, Bangera N, Simon BJ (2019) Exploration of the Impact of Brief
14 Noninvasive Vagal Nerve Stimulation on EEG and Event-Related Potentials.
15 *Neuromodulation Technol Neural Interface* 22:564–572 Available at:
16 <https://onlinelibrary.wiley.com/doi/abs/10.1111/ner.12864>.
- 17 Liu J, Fang J, Wang Z, Rong P, Hong Y, Fan Y, Wang X, Park J, Jin Y, Liu C, Zhu B, Kong J
18 (2016) Transcutaneous vagus nerve stimulation modulates amygdala functional
19 connectivity in patients with depression. *J Affect Disord* 205:319–326 Available at:
20 <http://dx.doi.org/10.1016/j.jad.2016.08.003>.
- 21 Liu Y, Rodenkirch C, Moskowitz N, Schriver B, Wang Q (2017) Dynamic Lateralization of
22 Pupil Dilation Evoked by Locus Coeruleus Activation Results from Sympathetic, Not
23 Parasympathetic, Contributions. *Cell Rep* 20:3099–3112 Available at:
24 <http://www.ncbi.nlm.nih.gov/pubmed/28954227>.
- 25 Manta S, Dong J, Debonnel G, Blier P (2009) Enhancement of the function of rat serotonin
26 and norepinephrine neurons by sustained vagus nerve stimulation. *J Psychiatry Neurosci*

- 1 34:272–280.
- 2 Manta S, Mansari M El, Debonnel G, Blier P (2013) Electrophysiological and neurochemical
3 effects of long-term vagus nerve stimulation on the rat monoaminergic systems. :459–
4 470.
- 5 Maris E, Oostenveld R (2007) Nonparametric statistical testing of EEG- and MEG-data. J
6 Neurosci Methods 164:177–190.
- 7 Meij R Van Der, Ede F Van, Maris E (2016) Rhythmic Components in Extracranial Brain
8 Signals Reveal Multifaceted Task Modulation of Overlapping Neuronal Activity. :1–28.
- 9 Miwakeichi F, Martínez-Montes E, Valdés-Sosa PA, Nishiyama N, Mizuhara H, Yamaguchi
10 Y (2004) Decomposing EEG data into space-time-frequency components using Parallel
11 Factor Analysis. Neuroimage 22:1035–1045 Available at:
12 <http://www.ncbi.nlm.nih.gov/pubmed/15219576>.
- 13 Mridha Z, Gee JW de, Shi Y, Alkashgari R, Williams J, Suminski A, Ward MP, Zhang W,
14 McGinley MJ (2019) Graded recruitment of pupil-linked neuromodulation by
15 parametric stimulation of the vagus nerve. bioRxiv:2019.12.28.890111 Available at:
16 <http://biorxiv.org/content/early/2019/12/30/2019.12.28.890111.abstract>.
- 17 Murphy PR, O’Connell RG, O’Sullivan M, Robertson IH, Balsters JH (2014) Pupil diameter
18 covaries with BOLD activity in human locus coeruleus. Hum Brain Mapp 35:4140–
19 4154 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24510607>.
- 20 Murphy PR, Robertson IH, Balsters JH, O’connell RG (2011) Pupillometry and P3 index the
21 locus coeruleus-noradrenergic arousal function in humans. Psychophysiology 48:1532–
22 1543.
- 23 Nemeroff CB, Mayberg HS, Krahl SE, McNamara J, Frazer A, Henry TR, George MS,
24 Charney DS, Brannan SK (2006) VNS therapy in treatment-resistant depression: clinical
25 evidence and putative neurobiological mechanisms. Neuropsychopharmacology
26 31:1345–1355 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16641939>.

- 1 Nieuwenhuis S, Aston-Jones G, Cohen JD (2005) Decision making, the P3, and the locus
2 coeruleus-norepinephrine system. *Psychol Bull* 131:510–532 Available at:
3 <http://doi.apa.org/getdoi.cfm?doi=10.1037/0033-2909.131.4.510>.
- 4 Nieuwenhuis S, De Geus EJ, Aston-Jones G (2011) The anatomical and functional
5 relationship between the P3 and autonomic components of the orienting response.
6 *Psychophysiology* 48:162–175 Available at:
7 <http://www.ncbi.nlm.nih.gov/pubmed/20557480>.
- 8 Nir Y, Tononi G (2010) Dreaming and the brain: from phenomenology to neurophysiology.
9 *Trends Cogn Sci* 14:88–100 Available at:
10 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2814941&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2814941&tool=pmcentrez&rendertype=abstract)
11 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2814941&tool=pmcentrez&rendertype=abstract) [Accessed May 28, 2014].
- 12 Oostenveld R, Fries P, Maris E, Schoffelen J-M (2011) FieldTrip: Open Source Software for
13 Advanced Analysis of MEG, EEG, and Invasive Electrophysiological Data. *Comput*
14 *Intell Neurosci* 2011:1–9.
- 15 Palva S, Palva JM (2007) New vistas for α -frequency band oscillations. *Trends Neurosci*
16 30:150–158.
- 17 Peirce JW (2007) PsychoPy--Psychophysics software in Python. *J Neurosci Methods* 162:8–
18 13 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17254636>.
- 19 Peuker ET, Filler TJ (2002) The nerve supply of the human auricle. *Clin Anat* 15:35–37.
- 20 Pineda JA, Swick D (1992) Visual P3-like potentials in squirrel monkey: Effects of a
21 noradrenergic agonist. *Brain Res Bull* 28:485–491 Available at:
22 <https://linkinghub.elsevier.com/retrieve/pii/036192309290051X>.
- 23 Pineda JA, Westerfield M, Kronenberg BM, Kubrin J (1997) Human and monkey P3-like
24 responses in a mixed modality paradigm: effects of context and context-dependent
25 noradrenergic influences. *Int J Psychophysiol* 27:223–240 Available at:
26 <https://linkinghub.elsevier.com/retrieve/pii/S0167876097000615>.

- 1 Raedt R, Clinckers R, Mollet L, Vonck K, El Tahry R, Wyckhuys T, De Herdt V, Carrette E,
2 Wadman W, Michotte Y, Smolders I, Boon P, Meurs A (2011) Increased hippocampal
3 noradrenaline is a biomarker for efficacy of vagus nerve stimulation in a limbic seizure
4 model. *J Neurochem* 117:461–469 Available at: [http://doi.wiley.com/10.1111/j.1471-](http://doi.wiley.com/10.1111/j.1471-4159.2011.07214.x)
5 4159.2011.07214.x.
- 6 Redgrave J, Day D, Leung H, Laud PJ, Ali A, Lindert R, Majid A (2018) Safety and
7 tolerability of Transcutaneous Vagus Nerve stimulation in humans; a systematic review.
8 *Brain Stimul* 11:1225–1238 Available at: <https://doi.org/10.1016/j.brs.2018.08.010>.
- 9 Reimer J, McGinley MJ, Liu Y, Rodenkirch C, Wang Q, McCormick DA, Tolia AS (2016)
10 Pupil fluctuations track rapid changes in adrenergic and cholinergic activity in cortex.
11 *Nat Commun* 7:13289 Available at: <http://www.nature.com/articles/ncomms13289>.
- 12 Rohleder N, Nater UM (2009) Determinants of salivary alpha-amylase in humans and
13 methodological considerations. *Psychoneuroendocrinology* 34:469–485 Available at:
14 <http://www.ncbi.nlm.nih.gov/pubmed/19155141>.
- 15 Rong P, Liu J, Wang L, Liu R, Fang J, Zhao J, Zhao Y, Wang H, Vangel M, Sun S, Ben H,
16 Park J, Li S, Meng H, Zhu B, Kong J (2016) Effect of transcutaneous auricular vagus
17 nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study.
18 *J Affect Disord* 195:172–179 Available at: <http://dx.doi.org/10.1016/j.jad.2016.02.031>.
- 19 Roosevelt RW, Smith DC, Clough RW, Jensen RA, Browning RA (2006) Increased
20 extracellular concentrations of norepinephrine in cortex and hippocampus following
21 vagus nerve stimulation in the rat. *Brain Res* 1119:124–132.
- 22 Safi S, Ellrich J, Neuhuber W (2016) Myelinated Axons in the Auricular Branch of the
23 Human Vagus Nerve. *Anat Rec* 299:1184–1191.
- 24 Salinsky MC, Burchiel KJ (1993) Vagus Nerve Stimulation Has No Effect on Awake EEG
25 Rhythms in Humans. *Epilepsia* 34:299–304.
- 26 Sellaro R, van Leusden JWR, Tona K-D, Verkuil B, Nieuwenhuis S, Colzato LS (2015)

- 1 Transcutaneous Vagus Nerve Stimulation Enhances Post-error Slowing. *J Cogn*
2 *Neurosci* 27:2126–2132 Available at:
3 http://www.mitpressjournals.org/doi/10.1162/jocn_a_00851.
- 4 Siegel JM (2005) Chapter 10 - REM Sleep. In: *Principles and Practice of Sleep Medicine*
5 (Fourth Edition), Fourth Edi. (Kryger MH, Roth T, Dement WC, eds), pp 120–135.
6 Philadelphia: W.B. Saunders. Available at:
7 <http://www.sciencedirect.com/science/article/pii/B0721607977500173>.
- 8 Steenbergen L, Sellaro R, Stock AK, Verkuil B, Beste C, Colzato LS (2015) Transcutaneous
9 vagus nerve stimulation (tVNS) enhances response selection during action cascading
10 processes. *Eur Neuropsychopharmacol* 25:773–778 Available at:
11 <http://dx.doi.org/10.1016/j.euroneuro.2015.03.015>.
- 12 Stefan H, Kreiselmeyer G, Kerling F, Kurzbuch K, Rauch C, Heers M, Kasper BS, Hammen
13 T, Rzonsa M, Pauli E, Ellrich J, Graf W, Hopfengärtner R (2012) Transcutaneous vagus
14 nerve stimulation (t-VNS) in pharmaco-resistant epilepsies: a proof of concept trial.
15 *Epilepsia* 53:e115-8 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22554199>.
- 16 Steriade M (2001) Impact of network activities on neuronal properties in corticothalamic
17 systems. *J Neurophysiol* 86:1–39 Available at:
18 <http://www.ncbi.nlm.nih.gov/pubmed/11431485>.
- 19 Sun L, Peräkylä J, Holm K, Haapasalo J, Lehtimäki K, Ogawa KH, Peltola J, Hartikainen KM
20 (2017) Vagus nerve stimulation improves working memory performance. *J Clin Exp*
21 *Neuropsychol* 00:1–11 Available at:
22 <https://www.tandfonline.com/doi/full/10.1080/13803395.2017.1285869>.
- 23 Sutton S, Braren M, Zubin J, John ER (1965) Evoked-potential correlates of stimulus
24 uncertainty. *Science* 150:1187–1188 Available at:
25 <http://www.ncbi.nlm.nih.gov/pubmed/5852977>.
- 26 Szerb JC (1967) Cortical acetylcholine release and electroencephalographic arousal. *J Physiol*

- 1 192:329–343 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6050151>.
- 2 Takigawa M, Mogenson GJ (1977) A study of inputs to antidromically identified neurons of
3 the locus coeruleus. *Brain Res* 135:217–230 Available at:
4 <http://www.ncbi.nlm.nih.gov/pubmed/922473>.
- 5 Torsvall L, Akerstedt T (1987a) Sleepiness on the job: continuously measured EEG changes
6 in train drivers. *Electroencephalogr Clin Neurophysiol* 66:502–511 Available at:
7 <http://www.ncbi.nlm.nih.gov/pubmed/2438115>.
- 8 Torsvall L, Akerstedt T (1987b) Sleepiness on the job: continuously measured EEG changes
9 in train drivers. *Electroencephalogr Clin Neurophysiol* 66:502–511.
- 10 Trevizol AP, Shiozawa P, Tairar I, Soares A, Gomes JS, Barros MD, Liquidato BM, Cordeiro
11 Q (2016) Transcutaneous Vagus Nerve Stimulation (taVNS) for Major Depressive
12 Disorder: An Open Label Proof-of-Concept Trial. *Brain Stimul* 9:453–454 Available at:
13 <http://dx.doi.org/10.1016/j.brs.2016.02.001>.
- 14 Tu Y, Fang J, Cao J, Wang Z, Park J, Jorgenson K, Lang C, Liu J, Zhang G, Zhao Y, Zhu B,
15 Rong P, Kong J (2018) A distinct biomarker of continuous transcutaneous vagus nerve
16 stimulation treatment in major depressive disorder. *Brain Stimul* 11:501–508 Available
17 at: <https://doi.org/10.1016/j.brs.2018.01.006>.
- 18 Van Bockstaele EJ, Peoples J, Telegan P (1999) Efferent projections of the nucleus of the
19 solitary tract to peri-Locus coeruleus dendrites in rat brain: Evidence for a monosynaptic
20 pathway. *J Comp Neurol* 412:410–428.
- 21 Van Leusden JWR, Sellaro R, Colzato LS (2015) Transcutaneous Vagal Nerve Stimulation
22 (tVNS): A new neuromodulation tool in healthy humans? *Front Psychol* 6:2013–2016.
- 23 van Stegeren AH (2008) The role of the noradrenergic system in emotional memory. *Acta*
24 *Psychol (Amst)* 127:532–541 Available at:
25 <https://linkinghub.elsevier.com/retrieve/pii/S0001691807001278>.

- 1 Varazzani C, San-Galli A, Gilardeau S, Bouret S (2015) Noradrenaline and dopamine neurons
2 in the reward/effort trade-off: a direct electrophysiological comparison in behaving
3 monkeys. *J Neurosci* 35:7866–7877 Available at:
4 <http://www.ncbi.nlm.nih.gov/pubmed/25995472>.
- 5 Ventura-Bort C, Wirkner J, Genheimer H, Wendt J, Hamm AO, Weymar M (2018) Effects of
6 Transcutaneous Vagus Nerve Stimulation (tVNS) on the P300 and Alpha-Amylase
7 Level: A Pilot Study. *Front Hum Neurosci* 12:202 Available at:
8 <http://www.ncbi.nlm.nih.gov/pubmed/29977196>.
- 9 Vonck K, Raedt R, Naulaerts J, De Vogelaere F, Thiery E, Van Roost D, Aldenkamp B,
10 Miatton M, Boon P (2014) Vagus nerve stimulation. . .25 years later! What do we know
11 about the effects on cognition? *Neurosci Biobehav Rev* 45:63–71 Available at:
12 <http://dx.doi.org/10.1016/j.neubiorev.2014.05.005>.
- 13 Warren CM, Tona KD, Ouwerkerk L, van Paridon J, Poletiek F, van Steenbergen H, Bosch
14 JA, Nieuwenhuis S (2018) The neuromodulatory and hormonal effects of transcutaneous
15 vagus nerve stimulation as evidenced by salivary alpha amylase, salivary cortisol, pupil
16 diameter, and the P3 event-related potential. *Brain Stimul* 12:1–8 Available at:
17 <https://doi.org/10.1016/j.brs.2018.12.224>.
- 18 Warren CM, Wilson RC, van der Wee NJ, Giltay EJ, van Noorden MS, Cohen JD,
19 Nieuwenhuis S (2017) The effect of atomoxetine on random and directed exploration in
20 humans. *PLoS One* 12:e0176034 Available at:
21 <http://www.ncbi.nlm.nih.gov/pubmed/28445519>.
- 22 Waschke L, Tune S, Obleser J (2019) Local cortical desynchronization and pupil-linked
23 arousal differentially shape brain states for optimal sensory performance. *Elife* 8
24 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/31820732>.
- 25 Wilcoxon F (1945) Individual Comparisons by Ranking Methods. *Biometrics Bull* 1:80
26 Available at: <https://www.jstor.org/stable/10.2307/3001968?origin=crossref>.

- 1 Yakunina N, Kim SS, Nam E-C (2017) Optimization of Transcutaneous Vagus Nerve
- 2 Stimulation Using Functional MRI. *Neuromodulation* 20:290–300 Available at:
- 3 <http://www.ncbi.nlm.nih.gov/pubmed/27898202>.
- 4 Yanagawa T, Chao ZC, Hasegawa N, Fujii N (2013) Large-scale information flow in
- 5 conscious and unconscious states: An ECoG study in monkeys. *PLoS One* 8:1–13.
- 6 Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T (2020) Critical Review
- 7 of Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical
- 8 Practice. *Front Neurosci* 14:284 Available at:
- 9 <http://www.ncbi.nlm.nih.gov/pubmed/32410932>.
- 10